PPP2R2B and hepatocellular carcinoma: Moreover, using MTS assay, EdU assay, and colony formation assay, we found that the cell proliferation ability of HCC cells was decreased under Sora treatment, and the effects were further aggravated by the co-treatment of PPP2R2B overexpression plasmid or PP2A agonists DT-061 and iHAP1 (Figure 5J-K), indicating that PP2A-B55β activation enhanced the inhibitory effect of Sora on the proliferation ability of HCC cells.